KOD
Kodiak Sciences Inc.
Biotechnology
Market Cap$2.31B
5Y Perf.+238.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
KOD vs OCUL
Revenue, margins, valuation, and 5-year total return — side by side.
OCUL
Ocular Therapeutix, Inc.
Biotechnology
Market Cap$2.12B
5Y Perf.+37.5%
KOD vs OCUL — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | KOD | OCUL |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $2.31B | $2.12B |
| Revenue (TTM) | $0.00 | $52M |
| Net Income (TTM) | $-217M | $-290M |
| Gross Margin | — | 87.2% |
| Operating Margin | — | -5.8% |
| Total Debt | $70M | $80M |
| Cash & Equiv. | $168M | $737M |
KOD vs OCUL — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
KOD
OCUL
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | 100 | 338.1 | +238.1% |
| Ocular Therapeutix,… (OCUL) | 100 | 137.5 | +37.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: KOD vs OCUL
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: KOD leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Ocular Therapeutix, Inc. is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
KOD
Kodiak Sciences Inc.
The Growth Play
KOD carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 32.6%
- 20.5% 10Y total return vs OCUL's -10.6%
- -15.7% revenue growth vs OCUL's -18.7%
Best for: growth exposure and long-term compounding
OCUL
Ocular Therapeutix, Inc.
The Income Pick
OCUL is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 1.27
- Lower volatility, beta 1.27, Low D/E 12.2%, current ratio 15.39x
- Beta 1.27, current ratio 15.39x
Best for: income & stability and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | KOD | -15.7% revenue growth vs OCUL's -18.7% |
| Quality / Margins | KOD | 3.3% margin vs OCUL's -5.6% |
| Stability / Safety | OCUL | Beta 1.27 vs KOD's 1.81, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | KOD | +10.3% vs OCUL's +37.3% |
| Efficiency (ROA) | OCUL | -48.4% ROA vs KOD's -99.7% |
KOD vs OCUL — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
KOD vs OCUL — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLOCULLAGGINGKOD
KODKodiak Sciences Inc.
1leads
OCULOcular Therapeutix, I…
2leads
6 Total Categories
CATEGORYLEADERvs KODMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
OCUL1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
OCUL6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
KOD6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
OCUL leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
OCUL and KOD operate at a comparable scale, with $52M and $0 in trailing revenue.
| Metric | KODKodiak Sciences I… | OCULOcular Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $52M |
| EBITDAEarnings before interest/tax | -$195M | -$295M |
| Net IncomeAfter-tax profit | -$217M | -$290M |
| Free Cash FlowCash after capex | -$127M | -$241M |
| Gross MarginGross profit ÷ Revenue | — | +87.2% |
| Operating MarginEBIT ÷ Revenue | — | -5.8% |
| Net MarginNet income ÷ Revenue | — | -5.6% |
| FCF MarginFCF ÷ Revenue | — | -4.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +0.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -38.1% | -5.3% |
OCUL leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — KOD and OCUL each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | KODKodiak Sciences I… | OCULOcular Therapeuti… |
|---|---|---|
| Market CapShares × price | $2.3B | $2.1B |
| Enterprise ValueMkt cap + debt − cash | $2.2B | $1.5B |
| Trailing P/EPrice ÷ TTM EPS | -13.04x | -6.82x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 40.90x |
| Price / BookPrice ÷ Book value/share | 15.28x | 2.77x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — KOD and OCUL each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
OCUL leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
OCUL delivers a -64.6% return on equity — every $100 of shareholder capital generates $-65 in annual profit, vs $-9 for KOD. OCUL carries lower financial leverage with a 0.12x debt-to-equity ratio, signaling a more conservative balance sheet compared to KOD's 0.47x. On the Piotroski fundamental quality scale (0–9), OCUL scores 4/9 vs KOD's 3/9, reflecting mixed financial health.
| Metric | KODKodiak Sciences I… | OCULOcular Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | -9.2% | -64.6% |
| ROA (TTM)Return on assets | -99.7% | -48.4% |
| ROICReturn on invested capital | -130.7% | — |
| ROCEReturn on capital employed | -50.0% | -46.0% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.47x | 0.12x |
| Net DebtTotal debt minus cash | -$98M | -$657M |
| Cash & Equiv.Liquid assets | $168M | $737M |
| Total DebtShort + long-term debt | $70M | $80M |
| Interest CoverageEBIT ÷ Interest expense | — | -24.63x |
OCUL leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
KOD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KOD five years ago would be worth $21,496 today (with dividends reinvested), compared to $5,957 for OCUL. Over the past 12 months, KOD leads with a +1028.7% total return vs OCUL's +37.3%. The 3-year compound annual growth rate (CAGR) favors KOD at 107.8% vs OCUL's 14.8% — a key indicator of consistent wealth creation.
| Metric | KODKodiak Sciences I… | OCULOcular Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | +67.9% | -18.1% |
| 1-Year ReturnPast 12 months | +1028.7% | +37.3% |
| 3-Year ReturnCumulative with dividends | +796.9% | +51.2% |
| 5-Year ReturnCumulative with dividends | +115.0% | -40.4% |
| 10-Year ReturnCumulative with dividends | +2051.7% | -10.6% |
| CAGR (3Y)Annualised 3-year return | +107.8% | +14.8% |
KOD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KOD and OCUL each lead in 1 of 2 comparable metrics.
Risk & Volatility
OCUL is the less volatile stock with a 1.27 beta — it tends to amplify market swings less than KOD's 1.81 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KOD currently trades 91.3% from its 52-week high vs OCUL's 58.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KODKodiak Sciences I… | OCULOcular Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.81x | 1.27x |
| 52-Week HighHighest price in past year | $47.84 | $16.44 |
| 52-Week LowLowest price in past year | $2.81 | $6.23 |
| % of 52W HighCurrent price vs 52-week peak | +91.3% | +58.9% |
| RSI (14)Momentum oscillator 0–100 | 61.7 | 58.3 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 4.0M |
Evenly matched — KOD and OCUL each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates KOD as "Buy" and OCUL as "Buy". Consensus price targets imply 163.4% upside for OCUL (target: $26) vs 48.1% for KOD (target: $65).
| Metric | KODKodiak Sciences I… | OCULOcular Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $64.67 | $25.50 |
| # AnalystsCovering analysts | 18 | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
OCUL leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). KOD leads in 1 (Total Returns). 2 tied.
Best OverallOcular Therapeutix, Inc. (OCUL)Leads 2 of 6 categories
Loading custom metrics...
KOD vs OCUL: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is KOD or OCUL a better buy right now?
Analysts rate Kodiak Sciences Inc.
(KOD) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KOD or OCUL?
Over the past 5 years, Kodiak Sciences Inc.
(KOD) delivered a total return of +115. 0%, compared to -40. 4% for Ocular Therapeutix, Inc. (OCUL). Over 10 years, the gap is even starker: KOD returned +20. 5% versus OCUL's -10. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KOD or OCUL?
By beta (market sensitivity over 5 years), Ocular Therapeutix, Inc.
(OCUL) is the lower-risk stock at 1. 27β versus Kodiak Sciences Inc. 's 1. 81β — meaning KOD is approximately 43% more volatile than OCUL relative to the S&P 500. On balance sheet safety, Ocular Therapeutix, Inc. (OCUL) carries a lower debt/equity ratio of 12% versus 47% for Kodiak Sciences Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — KOD or OCUL?
On earnings-per-share growth, the picture is similar: Kodiak Sciences Inc.
grew EPS 32. 6% year-over-year, compared to -16. 4% for Ocular Therapeutix, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — KOD or OCUL?
Kodiak Sciences Inc.
(KOD) is the more profitable company, earning 0. 0% net margin versus -513. 2% for Ocular Therapeutix, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KOD leads at 0. 0% versus -521. 0% for OCUL. At the gross margin level — before operating expenses — OCUL leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — KOD or OCUL?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is KOD or OCUL better for a retirement portfolio?
For long-horizon retirement investors, Ocular Therapeutix, Inc.
(OCUL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 27)). Kodiak Sciences Inc. (KOD) carries a higher beta of 1. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OCUL: -10. 6%, KOD: +20. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between KOD and OCUL?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.